Adaptive Biotechnologies Corporation
ADPT
$12.61
-$0.88-6.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 205.22M | 189.53M | 178.96M | 177.28M | 168.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 205.22M | 189.53M | 178.96M | 177.28M | 168.77M |
| Cost of Revenue | 55.31M | 57.84M | 58.92M | 50.26M | 57.31M |
| Gross Profit | 149.91M | 131.68M | 120.04M | 127.02M | 111.46M |
| SG&A Expenses | 159.25M | 156.10M | 157.57M | 160.57M | 163.33M |
| Depreciation & Amortization | 1.70M | 1.70M | 1.70M | 1.70M | 1.70M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 326.33M | 325.71M | 334.30M | 344.43M | 354.24M |
| Operating Income | -121.11M | -136.19M | -155.34M | -167.15M | -185.47M |
| Income Before Tax | -121.24M | -141.89M | -159.60M | -195.35M | -213.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -121.24 | -141.89 | -159.60 | -195.35 | -213.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 8.00K | 55.00K | 103.00K | 104.00K | 104.00K |
| Net Income | -121.23M | -141.84M | -159.49M | -195.24M | -213.47M |
| EBIT | -121.11M | -136.19M | -155.34M | -167.15M | -185.47M |
| EBITDA | -102.84M | -117.41M | -136.09M | -146.95M | -164.10M |
| EPS Basic | -0.81 | -0.96 | -1.09 | -1.34 | -1.47 |
| Normalized Basic EPS | -0.52 | -0.58 | -0.66 | -0.72 | -0.80 |
| EPS Diluted | -0.81 | -0.96 | -1.09 | -1.34 | -1.47 |
| Normalized Diluted EPS | -0.52 | -0.58 | -0.66 | -0.72 | -0.80 |
| Average Basic Shares Outstanding | 596.47M | 591.80M | 588.40M | 585.62M | 582.81M |
| Average Diluted Shares Outstanding | 596.47M | 591.80M | 588.40M | 585.62M | 582.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |